Guía de práctica clínica para el tratamiento de la psoriasis en Colombia
ACTUALIZACIÓN 2022
Resumen
El desarrollo científico en medicina y los recientes avances biotecnológicos exigen la necesidad de actualización permanente de las directrices para incorporar a la práctica clínica la mejor evidencia disponible para obtener los mejores resultados en los pacientes.¹ En concordancia, este documento actualiza el documento publicado en 2018 de la guía de práctica clínica para el tratamiento de la psoriasis en Colombia, de la Asociación Colombiana de Dermatología y Cirugía Dermatológica (AsoColDerma).Las preguntas no actualizadas de la guía junto con la evidencia pueden ser consultadas en la guía de práctica clínica para el tratamiento de la psoriasis en Colombia, publicada en 2018 y que se encuentra disponible en:https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1507
Referencias bibliográficas
Castro-Ayarza JRC, Franco MDF, Amador-Patarroyo JRA. Actualización de las Guías Colombianas de Psoriasis: una necesidad imperiosa. Rev Asoc Colomb Dermatol Cir Dermatológica. 2019;27(4):226-31.
Fundación Santafe, Centro de estudios de investigación en salud. Guía Metodológica para la elaboración de Guías de Práctica Clínica con Evaluación Económica en el Sistema General de Seguridad Social en Salud Colombiano. Versión completa final. 2014 pp: 195-200.
Colombia. Ministerio de Salud y Protección Social. Guía metodológica para la actualización de guías de práctica clínica en el sistema general de seguridad social en salud colombiano. Guía metodológica en Internet. Edición 1a. Bogotá DC. 2017.
Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. Marcos GRADE de la evidencia a la decisión (EtD): un enfoque sistemático y transparente para tomar decisiones sanitarias bien informadas. 1: Introducción. Gac Sanit. 2018;32(2):166.e1-166.e10.
Instituto de Evaluación Tecnológica en Salud. Manual de Procesos Participativos. Bogotá D.C.: IETS; 2014.
González Ardila C, Londoño García A, Castro-Gómez L. Guía de práctica clínica para el tratamiento del psoriasis en Colombia. Rev Asoc Colomb Dermatol Cir Dermatológica [Internet]. 2018; Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1507
Scottish Intercollegiate Guidelines Network (SIGN). SIGN 50: a guideline developer’s handbook. SIGN; 2014.
Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ. 2009;339(b2700).
Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66(7):726-35.
Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol. 2013;66(2):151-7.
Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311-6.
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407-15.
Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-6.
Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395-400.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94.
Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7(1):1-7.
Ministerio de Salud y Protección Social. Resolución 227 de 2020. Adopta lineamientos técnicos y operativos en el marco del Programa Nacional de Prevención y Control de la Tuberculosis (PNPCT). Pág 164 [Internet]. 2020. Disponible en: https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%20No.%20227%20de%202020.pdf
Zhang Z, Deng W, Wu Q, Sun L. Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. Immunotherapy. marzo de 2019;11(4):321-33.
Lee J, Kim E, Jang EJ, Lee CH, Lee EY, Im JP, Han SK, Yim JJ. Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist. Ann Am Thorac Soc. 2017 May;14(5):690-697. doi: https://doi.org/10.1513/annalsats.201608-647oc
Fowler E, Ghamrawi R, Ghiam N, Liao W, Wu J. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1449-56.
Puig L, Tsai TF, Bhutani T, Uy J, Ramachandran P, Song M, You Y, Gooderham M, Lebwohl M. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from p. J Eur Acad Dermatol Venereol. 2020;34(8):1744-9.
Huang YW, Tsai TF. A drug safety evaluation of risankizumab for psoriasis. Expert Opin Drug Saf. 2020 Apr;19(4):395-402. doi: https://doi.org/10.1080/14740338.2020.1736034 Epub 2020 Mar 5. PMID: 32100591.
Langley R, Blauvelt A, Gooderham M, Papp K, Philipp S, Wu JJ, et al. Efficacy and safety of continuous Q12W risankizumab versus treatment withdrawal: results from the phase 3 IMMhance trial. En MOSBY-ELSEVIER 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA; 2019. p. AB52-AB52.
Evangelatos G, Koulouri V, Iliopoulos A, Fragoulis GE. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis. 2020 Jun 22;12:1759720X20930116.
Tsai T, Ho V, Song M, Szapary P, Kato T, Wasfi Y, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145-52.
Hsiao CY, Chiu HY, Wang TS, Tsai TF. Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab. PLoS One. 2017;12(9):e0184178.
Pettipher C BR. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO). Ann Rheum Dis. 2020 Feb;79(2):292-299. doi: https://doi.org/10.1136/annrheumdis-2019-216128 Epub 2019 Dec 2. PMID: 31791950.
Gisondi P, Cazzaniga S, Chimenti S, Maccarone M, Picardo M, Girolomoni G, et al. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. Br J Dermatol. 2015;172(6):1613-20.
Conti A PS Gisondi P, Odorici G, Galdo G, Lasagni C, Pellacani G. Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatol Ther. 2017 Sep;30(5). doi: https://doi.org/10.1111/DTH.12503 Epub 2017 May 26. PMID: 28547750.
Instituto Nacional de Salud. Boletín Epidemiológico Semanal. Semana epidemiológica 11 14 al 20 de marzo de 2021 [Internet]. 2021. Disponible en: https://www.ins.gov.co/buscador-eventos/Boleti-nEpidemiologico/2021_Boletin_epidemiologico_semana_11.pdf
Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, et al. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatol Treat. 2017;28(6):492-9.
Gerdes S, Körber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. J Dermatol Treat. agosto de 2020;31(5):470-5.
Griffiths CEM, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet Lond Engl. agosto de 2015;386(9993):541-51.
Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Derm. 2021;
Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. abril de 2017;376(16):1551-60.
Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158-66.
Nishida E, Ikumi K, Muramatsu S, Kubo R, Morita A. 014 Absolute PASI values are important to achieve DLQI remission. J Invest Dermatol. 8 de septiembre de 2016;136(9):S163.
Norlin JM, Nilsson K, Persson U, Schmitt-Egenolf M. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. Br J Dermatol. 8 de septiembre de 2020;182(4):965-73.
Gkalpakiotis S, Cetkovska P, Arenberger P, Dolezal T, Arenbergerova M, Velackova B, et al. Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic. Dermatol Ther. 2021/06/05 ed. agosto de 2021;11(4):1345-55.
Hernández Mantilla N, Londoño García Á. PASI 90 y PASI absoluto: ¿por qué debemos cambiar las metas de tratamiento en psoriasis? Rev Asoc Colomb Dermatol Cir Dermatológica. 2020;28(1):58-62.
Amatore F, Villani A, Tauber M, Viguier M, Guillot B, Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie). French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464-83.
Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. enero de 2020;1(1):CD011535.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Puig L, et al. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatol Ther. 2021/03/31 ed. junio de 2021;11(3):885-905.
Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORAS, a phase 3 study. J Am Acad Dermatol. enero de 2019;80(1):70-79.e3.
Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A, et al. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J Eur Acad Dermatol Venereol JEADV. enero de 2021;35(1):135-42.
Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with mo-derate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. enero de 2017;76(1):60-69.e9.
Langley R, Elewski B, Lebwohl M, Reich K, Griffiths C, Papp K, et al. Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials. N Engl J Med. 9 de julio de 2014;371.
Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator. J Am Acad Dermatol. marzo de 2017;76(3):405-17.
Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet Lond Engl. septiembre de 2019;394(10201):831-9.
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet Lond Engl. agosto de 2018;392(10148):650-61.
Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. enero de 2021;184(1):50-9.
Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, et al. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). Am J Clin Dermatol. abril de 2017;18(2):273-80.
Georgakopoulos J, Phung M, Ighani A, Lam K, Yeung J. Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. J Eur Acad Dermatol Venereol JEADV. 2018;33(1):e7-8.
Bokor-Billmann T, Schäkel K. No need to change the drug class: ixekizumab-following secukinumab-therapy in psoriasis. J Dermatol Treat. 2019;30(3):216-20.
Georgakopoulos JR, Phung M, Ighani A, Yeung J. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol. 2018;79(1):155-7.
Warren RB, Barker JNWB, Finlay AY, Burden AD, Kirby B, Armendariz Y, et al. Secukinumab for patients failing previous tumour necrosis factor-αinhibitor therapy: results of a randomized open-label study (SIGNATURE). Br J Dermatol. julio de 2020;183(1):60-70.
Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, et al. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. J Drugs Dermatol JDD. agosto de 2018;17(8):826-32.
Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, VOYAGE 2. J Am Acad Dermatol. marzo de 2017;76(3):418-31.
Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. enero de 2018;178(1):114-23.
Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet Lond Engl. agosto de 2019;394(10198):576-86.
Griffiths CEM, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. enero de 2010;362(2):118-28.
Foley P, Strober B, Valdecantos WC. Durable Efficacy of Risankizumab Compared with Ustekinumab Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Integrated Analysis of Two Phase 3 Trials. Am Acad Dermatol. 2019;81(4):AB49.
González Ardila C, Londoño García A, Castro Gómez L, (editores), AsoColDerma. Asociación Colombiana de Dermatología y Cirugía Dermatológica; Grupo Colombiano de Psoriasis y Artritis Psoriásica. Guías basadas en la evidencia para el manejo del psoriasis en Colombia; 2012.
Grace E, Goldblum O, Renda L, Agada N, See K, Leonardi C, et al. Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis. Dermatol Ther. febrero de 2020;10(1):99-106.
Lockwood SJ, Prens LM, Kimball AB. Adverse Reactions to Biologics in Psoriasis. Curr Probl Dermatol. 2018;53:1-14.
Ghorbanibirgani A, Fallahi-Khoshknab M, Zarea K, Abedi H. The Lived Experience of Psoriasis Patients from Social Stigma and Rejection: A Qualitative Study. Iran Red Crescent Med J. 21 de mayo de 2016;18(7):e27893-e27893.
Meneguin S, de Godoy NA, Pollo CF, Miot HA, de Oliveira C. Quality of life of patients living with psoriasis: a qualitative study. BMC Dermatol. 2020;20(1):22.
Trettin B, Feldman SR, Andersen F, Danbjørg DB, Agerskov H. A changed life: the life experiences of patients with psoriasis receiving bio-logical treatment. Br J Dermatol. septiembre de 2020;183(3):516-23.
Alsenaid A, Ezmerli M, Srour J, Heppt M, Illigens BM, Prinz JC. Biologics and small molecules in patients with scalp psoriasis: a systematic review. J Dermatol Treat. junio de 2020;1-10.
Camela E, Ocampo-Garza SS, Cinelli E, Villani A, Fabbrocini G, Megna M. Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. Dermatol Ther. marzo de 2021;34(2):e14857.
Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatol Treat. junio de 2017;28(4):282-7.
Paller AS, Seyger MMB, Magariños GA, Bagel J, Pinter A, Cather J, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 29 de julio de 2020;183(2):231-41.
Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. octubre de 2017;77(4):667-74.
Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, et al. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol. 1 de junio de 2018;154(6):676-83.
Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, Santiago-Vázquez M, Cancel-Artau KJ, Arias-Berrios G, et al. Treatment of erythrodermic psoriasis with biologics: A systematic review. J Am Acad Dermatol. julio de 2020;83(1):151-8.
Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ. A systematic review of treatment strategies for erythrodermic psoriasis. J Dermatol Treat. 2 de enero de 2021;32(1):49-55.
Beck, K. M., Yang, E. J., Sanchez, I. M., & Liao, W. (2018). Treatment of genital psoriasis: a systematic review. Dermatology and therapy, 8(4), 509-525.
Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Yang F. Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis. SKIN J Cutan Med. 2018;2(S8).
Zhang X, Xie B, He Y. Efficacy of Systemic Treatments of Nail Psoriasis: A Systemic Literature Review and Meta-Analysis. Vol. 8, Frontiers in medicine. 2021. p. 620562.
Reich K, Conrad C, Kristensen LE, Smith SD, Puig L, Rich P, et al. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J Dermatol Treat. marzo de 2021;1-9.
Szebényi J, Gede N, Hegyi P, Szakács Z, Solymár M, Erőss B, et al. Efficacy of Biologics Targeting Tumour Necrosis Factor-alpha, Interleukin-17 -12/23, -23 and Small Molecules Targeting JAK and PDE4 in the Treatment of Nail Psoriasis: A Network Meta-analysis. Acta Derm Venereol. noviembre de 2020;100(18):adv00318.
Huang IH, Wu PC, Yang TH, Li H, Huang YT, Cheng YC, et al. Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis. J Am Acad Dermatol. julio de 2021;85(1):135-43.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79-87.
Wasel N, Thaçi D, French LE, Conrad C, Dutronc Y, Gallo G, et al. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatol Ther. agosto de 2020;10(4):663-70.
Reich K, Sullivan J, Arenberger P, Jazayeri S, Mrowietz U, Augustin M, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. marzo de 2021;184(3):425-36.
Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol JEADV. diciembre de 2014;28(12):1670-5.
Elewski BE, Baker CS, Crowley JJ, Poulin Y, Okun MM, Calimlim B, et al. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial. J Eur Acad Dermatol Venereol 2019;33(11):2168-78.
Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet Lond Engl. octubre de 2005;366(9494):1367-74.
Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriasis arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225-31.
Kristensen LE, Soliman AM, Papp K, Merola JF, Barcomb L, Wang Z, et al. Effects of Risankizumab on Nail Psoriasis in Patients with Active Psoriatic Arthritis: Results from KEEPsAKE1. J Eur Acad Dermatol Venereol. 2022; 36(5):e389-e392
Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. febrero de 2014;170(2):398-407.
Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. octubre de 2018;27(10):1067-77.
Falto-Aizpurua LA, Martin-Garcia RF, Carrasquillo OY, Nevares-Pomales OW, Sánchez-Flores X, Lorenzo-Rios D. Biological therapy for pustular psoriasis: a systematic review. Int J Dermatol. marzo de 2020;59(3):284-96.
Zhou LL, Georgakopoulos JR, Ighani A, Yeung J. Systemic monotherapy treatments for generalized pustular psoriasis: a systematic review. J Cutan Med Surg. 2018;22(6):591-601.
Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human inter-leukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. mayo de 2018;45(5):529-39.
Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Inhibition of the inter-leukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981-3.
Mrowietz U, Burden AD, Pinter A, Reich K, Schäkel K, Baum P, et al. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study. Dermatol Ther. 2021;11(2):571-85.
Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. abril de 2011;147(4):429-36.
Bissonnette R, Poulin Y, Guenther L, Lynde CW, Bolduc C, Nigen S. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol JEADV. diciembre de 2011;25(12):1402-8.
Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol JEADV. octubre de 2017;31(10):1686-92.
Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. enero de 2017;76(1):70-80.
Bachelez H, Chih-Ho HH, Pinter A. Efficacy and safety of risankizumab compared with placebo in patients with moderate-to-severe psoriasis: integrated analyses from three phase 3 trials. En: Poster. Paris, France; 2018.
Elewski B, Rich P, Crowley J, Foley P, Zhan T, Zhao Y. Efficacy and Safety of Long-Term Risankizumab Treatment for Nail, Scalp, and Palmoplantar Psoriasis: An Interim Analysis from the Open-Label Extension LIMMitless Trial. Abstr 29th Eur Acad Dermatol Venereol. 2020;29-31.
Elewski B, Rich P, Crowley J, Foley P, Wu T, Reyes Servin O. Risankizumab profile in nail, scalp, and palmoplantar psoriasis: efficacy and safety at 52 weeks in an integrated analysis of patients with moderate-to-severe plaque psoriasis. En: Poster 4251. Milan, Italy; 2019.
Au SC, Goldminz AM, Kim N, Dumont N, Michelon M, Volf E, et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatol Treat. 2013;24(3):179-87.
Chiang CY, Tsai TF. Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab. Dermatol Ther. 2021;11(1):301-6.
Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet Lond Engl. 2017;390(10089):40-9.
Thaçi D, Papp K, Marcoux D, Weibel L, Pinter A, Ghislain P, et al. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol. 2019;181(6):1177-89.
Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(2):280-3.
Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-se-vere plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594-603.
Philipp S, Menter A, Nikkels AF, Barber K, Lan-dells I, Eichenfield LF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. octubre de 2020;183(4):664-72.
Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol JEADV. 2021;35(4):938-47.
Gutknecht M, Krensel M, Augustin M. Health economic analyses of psoriasis management: a systematic literature search. Arch Dermatol Res. 2016;308(9):601-16.
Zidane M, Dressler C, Gaskins M, Nast A. Decision-analytic modeling for time-effectiveness of the sequence of induction treatments for moderate to severe plaque psoriasis. JAMA Dermatol. 2019;155(12):1380-9.
Lakdawalla DN, Doshi JA, Garrison Jr LP, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care—a health economics approach: an ISPOR Special Task Force report [3]. Value Health. 2018;21(2):131-9.
Lakdawalla D, Malani A, Reif J. The insurance value of medical innovation. J Public Econ. 2017;145:94-102.
Garrison Jr LP, Kamal-Bahl S, Towse A. Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis. Value Health. 2017;20(2):213-6
